Metabotropic glutamate receptors (mGluRs), particularly striatal mGluR5 and mGluR2/3, are promising targets for PD treatment due to their roles in modulating presynaptic glutamate release, intracellular Ca2+ levels, and neuroprotection. This evidence concerns the gene GRM5 and Parkinson disease.